Dalal, S., Shingles, J., Girvan, S., Cairns, D., Glover, P., Warren, H., Grand, T., Webster, N., Rawstron, A., Newton, D., Evans, C., Tute, R. D., Hockaday, A., Jackson, S., Bell, S., Greatorex, N., Stones, D., Allsup, D., Bloor, A., Sarma, A., Varghese, A. M., Hillmen, P., Munir, T. (2025). MRD-guided ibrutinib plus venetoclax improves outcomes in CLL patients with TP53, ATM, or NOTCH1 aberrations compared to ibrutinib and FCR: Results from the Phase III NCRI FLAIR trial. Blood. https://doi.org/10.1182/blood-2025-679